Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ERO1A | Q96HE7 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1473800 | 0.89 | MEN1 (0.46) | RAD51PTGS1PTGS2HTR2CKMT2A | |
| SCHEMBL1471690 | 0.83 | HTR2C (0.44) | PTGS1PTGS2HTR2CKMT2AALDH1A1 | |
| SCHEMBL1471674 | 0.81 | KMT2A (0.40) | RAD51KMT2AALDH1A1MEN1GAA | |
| SCHEMBL1471684 | 0.81 | KMT2A (0.44) | RAD51KMT2AALDH1A1MEN1GAA | |
| SCHEMBL1473725 | 0.78 | RAD51 (0.46) | RAD51KMT2AALDH1A1MEN1GAA | |
| SCHEMBL1471837 | 0.78 | MAPT (0.51) | RAD51HTR2CKMT2AALDH1A1MEN1 | |
| SCHEMBL1473798 | 0.78 | KMT2A (0.41) | RAD51PTGS2KMT2AALDH1A1MEN1 | |
| SCHEMBL1471762 | 0.76 | MAPT (0.46) | RAD51KMT2AALDH1A1MEN1GAA | |
| SCHEMBL1471669 | 0.72 | RAD51 (0.46) | RAD51KMT2AALDH1A1MEN1LMNA | |
| SCHEMBL1471340 | 0.72 | IDO1 (0.44) | RAD51KMT2AALDH1A1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091531-B1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S R L (IT) | 2010-11-24 | — | — | EP | claimed |
| US-20100099736-A1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S.R.L. (IT) | 2010-04-22 | — | — | US | claimed |
| EP-2091531-A2 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | Congenia S.r.l. (IT) | 2009-08-26 | — | — | EP | claimed |
| WO-2008067863-A2 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S.R.L. (IT) | 2008-06-12 | — | — | WO | claimed |
| WO-2016144352-A2 | THERAPEUTIC COMPOSITIONS INCLUDING ACRYLAMIDO COMPOUNDS OR PHENYL-SUBSTITUTED MALEIMIDE COMPOUNDS, VARIANTS THEREOF AND METHODS OF USING THE SAME | STEALTH PEPTIDES INTERNATIONAL, INC. (MC) | 2016-09-15 | — | — | WO | disclosed |
| US-7915304-B2 | Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT | CONGENIA S.R.L. (IT) | 2011-03-29 | — | — | US | disclosed |
| EP-2091531-B1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S R L (IT) | 2010-11-24 | — | — | EP | disclosed |
| US-20100099736-A1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
| EP-2091531-A2 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | Congenia S.r.l. (IT) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008067863-A2 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S.R.L. (IT) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099736-A1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CYC1, MTPN, TXN2 | RAD51 3231/4885EGFR 3627/4885PTGS1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.